Background: Quantifying the degree of HIV persistence during therapy is challenging due to low viral burden and the intracellular sequestration of virus. An alternative or complementary approach is to quantify the host response to HIV. HIV incidence assays have been developed to measure antibody (Ab) evolution during HIV seroconversion. We used HIV incidence assays to investigate the association between HIV Ab levels, avidity and HIV antigen specificities in a diverse cohort of treated and untreated adults. Methodology: HIV incidence assays included: dilution (1:400 dilution in buffer; increased cutoff) for the VITROSR Anti-HIV1+2 assay; an avidity (DEAincubation/ PBS-incubation; avidity index) modification for the BIO-RAD GS HIV-1/2 assay; and an index summing HIV-specific band intensities targeting p31, gp160, gp41 for the Geenius™ HIV1/2 supplemental assay. Using these methods we characterized HIV Ab responses from 280 long-term infected untreated individuals, 280 treated and suppressed individuals, 100 suppressed elite controllers (EC) and one potentially eradicated individual (the Berlin patient). We also observed responses in longitudinal follow-up after HAART. Results: Compared to individuals with untreated HIV infection, EC exhibited lower levels of HIV Ab by both LS-VITROS (p<0.001) and Geenius (p=0.01) quantitative assays, but no difference in antibody avidity by the Bio-Rad avidity assay. EC had higher Ab levels compared to ART-treated suppressed patients in all assays (p<0.001). Subjects treated in acute infection had lower Ab levels on all assays compared to those treated in chronic infection. Among subjects treated with suppressive ART after complete seroconversion, increasing time on treatment was correlated with lower Ab levels by LS-VITROS (p=0.001) and Geenius (p=0.01), but no decline was seen in Ab avidity by the Bio-Rad assay. The Berlin patient has low-level Ab that has progressively declined over time on these assays, consistent with complete absence of virus (eradication). Conclusions: There are reductions in Ab titer but not in avidity in treated compared to untreated individuals that correlates with time on treatment. Although EC had undetectable or very low VL, Ab levels remained elevated compared to individuals on ART, demonstrating maintenance of Ab stimulation from persistent viral replication in reservoirs. Measuring the quantity, quality and diversity of Ab to HIV may be used as a marker for monitoring viral persistence in studies of eradication and treatment.